An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma
{{output}}
Glioblastoma (GBM) is a devastating brain cancer with a 5-year survival rate of ∼5% despite current treatment regimens. Multiple oncolytic herpes simplex viruses (oHSV) have been designed for GBM therapy, but clinical trials have thus far met with limited suc... ...
